Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations.
about
Fumarase: a mitochondrial metabolic enzyme and a cytosolic/nuclear component of the DNA damage responseThe FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiencyStructural and mechanistic studies on the inhibition of the hypoxia-inducible transcription factor hydroxylases by tricarboxylic acid cycle intermediatesUBE2QL1 is disrupted by a constitutional translocation associated with renal tumor predisposition and is a novel candidate renal tumor suppressor geneInactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localizationMetabolism of kidney cancer: from the lab to clinical practiceApplications of metabolomics in cancer researchRegulation of human metabolism by hypoxia-inducible factorState of the science: an update on renal cell carcinomaOncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenasesCell-permeating alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cellsMetabolic, autophagic, and mitophagic activities in cancer initiation and progressionHypoxia-Inducible Histone Lysine Demethylases: Impact on the Aging Process and Age-Related DiseasesBreast Cancer Metabolism and Mitochondrial Activity: The Possibility of Chemoprevention with MetforminCancer Metabolism and Drug ResistanceDecoding Warburg's hypothesis: tumor-related mutations in the mitochondrial respiratory chainSuccinate Dehydrogenase Loss in Familial Paraganglioma: Biochemistry, Genetics, and EpigeneticsAscorbate as a co-factor for fe- and 2-oxoglutarate dependent dioxygenases: physiological activity in tumor growth and progressionCancer metabolism: key players in metabolic reprogrammingMitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel?Physiological consequences of complex II inhibition for aging, disease, and the mKATP channelTargeted therapeutic strategies for the management of renal cell carcinomaPancreatic cancer early detection: expanding higher-risk group with clinical and metabolomics parametersProtein lysine acylation and cysteine succination by intermediates of energy metabolismIDH mutations in tumorigenesis and their potential role as novel therapeutic targets.Oncometabolites: Unconventional triggers of oncogenic signalling cascadesChanging perspective on oncometabolites: from metabolic signature of cancer to tumorigenic and immunosuppressive agentsThe ever-expanding role of HIF in tumour and stromal biologyRegulation of succinate-ubiquinone reductase and fumarate reductase activities in human complex II by phosphorylation of its flavoprotein subunitInhibition of 2-oxoglutarate dependent oxygenasesRedox regulation of mitochondrial functionHypoxia-inducible factor-1alpha regulates beta cell function in mouse and human isletsThe role of PHD2 mutations in the pathogenesis of erythrocytosis.Role of mitochondrial dysfunction in cancer progressionThe role of angiogenic factors in fibroid pathogenesis: potential implications for future therapyRisk-oriented approach to hereditary adrenal pheochromocytoma.Mitochondrial reactive oxygen species production in excitable cells: modulators of mitochondrial and cell function.Warburg effect's manifestation in aggressive pheochromocytomas and paragangliomas: insights from a mouse cell model applied to human tumor tissue.Birt-Hogg-Dubé: tumour suppressor function and signalling dynamics central to folliculin.Somatic pairing of chromosome 19 in renal oncocytoma is associated with deregulated EGLN2-mediated [corrected] oxygen-sensing response.
P2860
Q21145799-FB6BD9BC-F054-457D-8CAF-3A06B05307ACQ21261429-F2D3B000-417F-47F7-AC94-0B717590909EQ24321241-5D93093C-AA30-4C65-A593-E0643AFB2BB5Q24321830-A92E017E-CC19-463A-AD64-85ECDF355E4AQ24324012-F8EEDC30-8A0D-4900-A68D-505EA676C28DQ24600512-5775C2FA-3742-4215-A3D8-5CA139D88B0CQ24600728-D5181F1F-A53D-4A5D-9317-4D073116871BQ24606874-C956B6BA-B0C8-4262-95A4-2358DA3EC8D1Q24630685-2463122D-3749-4F2C-ADC9-144286080E82Q24632807-2C5F8CB0-AD5A-47AA-91ED-2146C6AE6F75Q24683296-1C6AC046-D642-4CD4-B49C-541FAFB1F361Q26745503-1D396F1A-6C4A-4FC4-8DB7-FB74E5261E61Q26750099-77D711BE-123A-4089-9B05-E782B30CD207Q26775580-D8F7E4E3-BD6A-40B0-B858-140B3230D2E6Q26782042-EEE44B24-434E-4090-AD9D-3EF11C55C171Q26783724-FB6E9F78-E47F-4B9B-82D5-645DBBD725C3Q26796203-261F0BA6-5B88-4E68-8EA2-511085506899Q26822640-6D63A63A-73D3-497C-9F27-B3E4D6C4DB55Q26827663-9873FCDA-6FC7-403F-BD00-D50B59851C6BQ26852282-F28126DF-9066-45A2-B302-C743480B3125Q27002338-F3D4D70F-FBFB-4CD5-AB74-179DC2928C81Q27013846-A617FEB4-BDBA-4B33-8B85-48B8E6F4F720Q27022231-D106A06F-5CE1-41E3-A361-129BC8FA8C86Q27027406-1EF05838-604F-41A2-870E-1882A7E8420BQ27692015-E80FF6F3-A160-4FBF-AF6F-DBF6596AE6ECQ28069594-BF0D84DC-ACE9-43F1-B062-E709D1E4A67DQ28073524-F2CEF8E3-1B61-4BA0-A410-D12C555336C4Q28079015-18B9C9A3-3537-4223-8860-F3051285401BQ28253467-0CA55E53-C72A-4BD0-8DFA-55B1C9EBA4FDQ28306956-CCD47B05-041C-4BAF-A067-E7FF9D633478Q28383361-9C7F5AEC-D254-48AD-B786-8A8E406A2D94Q28591503-9340E096-E8D2-48F7-99A6-C83989A27E8AQ28598099-B200C8EE-33C2-45BC-8480-1EBD5B8AF356Q28829644-3B968168-5317-4CA6-BC6D-6C91D02C82C6Q29040166-BA0F9555-2250-433D-94C8-F6F4DEA85085Q30319928-7C1F2AD3-722F-426E-96E2-EF835C3D2672Q30374674-2DC621FE-E01B-47A3-81A8-FC4BAF613BA3Q31079334-E7705819-E6E0-4FC5-85B7-BBB7F5E3E582Q33354615-19B14480-737E-4285-A8A7-86D46C924587Q33367131-83A13627-860F-458D-8373-EA9E12249D92
P2860
Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Accumulation of Krebs cycle in ...... germline FH and SDH mutations.
@en
Accumulation of Krebs cycle in ...... germline FH and SDH mutations.
@nl
type
label
Accumulation of Krebs cycle in ...... germline FH and SDH mutations.
@en
Accumulation of Krebs cycle in ...... germline FH and SDH mutations.
@nl
prefLabel
Accumulation of Krebs cycle in ...... germline FH and SDH mutations.
@en
Accumulation of Krebs cycle in ...... germline FH and SDH mutations.
@nl
P2093
P2860
P356
P1476
Accumulation of Krebs cycle in ...... germline FH and SDH mutations.
@en
P2093
Dalgleish A
Gleeson MJ
Griffiths JR
Hargreaves IP
P2860
P304
P356
10.1093/HMG/DDI227
P577
2005-06-29T00:00:00Z